| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/25/2002 | US20020049158 Increasing bioavailability of a drug which is not readily absorbed in the digestive tract |
| 04/25/2002 | US20020049154 Bioconjugates and delivery of bioactive agents |
| 04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
| 04/25/2002 | US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases |
| 04/25/2002 | US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor |
| 04/25/2002 | US20020048764 Human PEM as a target for birth contol and treatment of Alzheimer's disease |
| 04/25/2002 | US20020048748 Controlling human lymphocyte leukemia/lymphoma viruses immunodeficiency virus; obtain human, administer viricide and interleukin, monitor human for adjust in viral activity |
| 04/25/2002 | US20020048612 GABA substrate and the use thereof for treating cognitive and emotional disorders |
| 04/25/2002 | US20020048611 Anti-microbial-adhesion fraction derived from vaccinium |
| 04/25/2002 | US20020048608 Immunostimulator for animals and humans, and method of preventing animal and human infectious diseases and cancer |
| 04/25/2002 | US20020048606 Method of preparing microparticles of one or more phytosterols, phytostanols or mixtures of both |
| 04/25/2002 | US20020048605 Fluidity improver and/or anti-agglomeration agent, and a hydrophobic, moisture-proof layer is arranged on the surface of the particles; use in animal feeds, cosmetics and drugs |
| 04/25/2002 | US20020048602 Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| 04/25/2002 | US20020048600 Residual drug content in the device is minimized by the utilization of a flow-promoting layer between a semi-permeable wall; delivery devices having high drug loading |
| 04/25/2002 | US20020048599 Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| 04/25/2002 | US20020048587 Containing an antigen or at least one in vivo generator of a compound comprising an amino acid sequence. |
| 04/25/2002 | US20020048581 Modulating Protein Kinase C beta; useful in the treatment of insulin-related disorders, e.g., hypertension. |
| 04/25/2002 | US20020048580 Method of inducing lung branching |
| 04/25/2002 | US20020048578 Modified version of a therapeutic antibody with affinity for a cell-surface antigen; capable of inducing immunological tolerance to the therapeutic antibody |
| 04/25/2002 | US20020048572 Modulating expression of a mammalian SREBP-1 gene in a cell that comprises an SREBP-1 gene and an LXR alpha polypeptide. |
| 04/25/2002 | US20020048565 Mammalian tolloid-like gene and protein |
| 04/25/2002 | US20020048561 Synthetic soil-extract materials and medicaments for human immunodeficiency viruses based thereon |
| 04/25/2002 | US20020048558 Topical delivery systems for active agents |
| 04/25/2002 | US20020048555 Artificial tanning compositions comprising flavylium salts |
| 04/25/2002 | US20020048551 Nutritional supplements that are encapsulated in lipid vesicles for administration as an aerosol or liquid droplet spray. |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | DE10053056A1 Use of 11-keto-beta-boswellic acid, in treatment of inflammatory diseases e.g. bronchial asthma, ulcerative colitis, chronic polyarthritis, gout, brain tumors and multiple sclerosis, as selective 5-lipoxygenase inhibitor |
| 04/25/2002 | DE10051716A1 Composition for treating viral infections, especially caused by retro- or hepatitis viruses, comprises proteosome inhibitor that prevents release, maturation or replication |
| 04/25/2002 | DE10051321A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are potent neurokinin antagonists, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10051320A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are neurokinin antagonists having a long duration of action, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10050236A1 Use of specified compounds as sigma-receptor ligands, useful for treating carcinomas and sarcomas |
| 04/25/2002 | DE10048596A1 Diterpenes with a labdane structure, useful as antiinflammatory agents in therapeutic and cosmetic compositions for treatment of arthritis, asthma, psoriasis, skin erythema or irritation |
| 04/25/2002 | DE10034673C1 Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung Dermal application system for aminolevulinic acid and its use |
| 04/25/2002 | CA2818654A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464121A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464092A1 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | CA2426604A1 Compounds with high monoamine transporter affinity |
| 04/25/2002 | CA2426593A1 Ketolide antibacterials |
| 04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426337A1 Substituted imidazoles useful in the treatment of inflammatory diseases |
| 04/25/2002 | CA2426271A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | CA2426175A1 Stable oral formulation containing benzimidazole derivative |
| 04/25/2002 | CA2426148A1 Aromatic and heterocyclic thiazolyl thiourea compounds and use |
| 04/25/2002 | CA2426120A1 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | CA2426103A1 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents |
| 04/25/2002 | CA2426097A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 04/25/2002 | CA2426083A1 Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis |
| 04/25/2002 | CA2425831A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |
| 04/25/2002 | CA2425823A1 Use of olive oil in the preparation of a product for oral hygiene for the elimination or reduction of bacterial plaque and/or bacteria present in the buccal cavity |
| 04/25/2002 | CA2425742A1 Methods of selecting compounds for modulation of bladder function |
| 04/25/2002 | CA2425727A1 Methods and compositions for promoting the maturation of monocytes |
| 04/25/2002 | CA2425701A1 Indole compounds as minimally physiologial function monitioring agents |
| 04/25/2002 | CA2425698A1 Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients |
| 04/25/2002 | CA2425563A1 Novel m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence |
| 04/25/2002 | CA2425522A1 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/25/2002 | CA2425514A1 S-adenosylmethionine and derivatives thereof for the treatment and prevention of alzheimer's disease |
| 04/25/2002 | CA2425174A1 Human gene critical to fertility |
| 04/25/2002 | CA2424729A1 Estrogen receptor modulators |
| 04/25/2002 | CA2424726A1 Estrogen receptor modulators |
| 04/25/2002 | CA2424689A1 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | CA2424356A1 Supercritical co2 extraction of tetrahydrocannabinol and cannabidiol from cannabis plant material |
| 04/25/2002 | CA2424345A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | CA2423933A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | CA2423792A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | CA2423789A1 Bridged piperazine derivatives |
| 04/25/2002 | CA2423599A1 Methods of producing oxazolidinone compounds |
| 04/25/2002 | CA2423469A1 Methods and products related to pulmonary delivery of polysaccharides |
| 04/25/2002 | CA2423013A1 Use of inhibitors of progesteron receptor for treating cancer |
| 04/25/2002 | CA2421597A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | CA2420994A1 Method of treating stroke |
| 04/25/2002 | CA2420012A1 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance |
| 04/25/2002 | CA2405906A1 Remedies or preventives for rheumatoid arthritis |
| 04/24/2002 | EP1199307A1 Pharmaceutically active benzoquinazoline compounds |
| 04/24/2002 | EP1199304A1 Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders |
| 04/24/2002 | EP1199078A1 Analgesics |
| 04/24/2002 | EP1199077A1 Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers |
| 04/24/2002 | EP1199076A2 Medicament containing tocotrienol as active component |
| 04/24/2002 | EP1199075A2 Use of vitamine E metabolites alpha-CEHC and gamma-CEHC as antioxidants |
| 04/24/2002 | EP1199074A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/24/2002 | EP1199073A1 Aminoethanesulfonic acid-containing preparations |
| 04/24/2002 | EP1199072A2 Method of treating cartilage damage |
| 04/24/2002 | EP1199071A2 Use of an estrogen agonist/antagonist for improving vascular health |
| 04/24/2002 | EP1199070A2 Use of PDE V inhibitors for improved fecundity in mammals |
| 04/24/2002 | EP1199069A2 Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health |
| 04/24/2002 | EP1199068A2 NMDA NR2B antagonists for treating depression and neurodegenerative disorders |
| 04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |
| 04/24/2002 | EP1198995A1 Anti-stress composition for incorporation in nutritional carriers |
| 04/24/2002 | EP1198994A2 Health food products |
| 04/24/2002 | EP1198709A1 Glycosaminoglycan metabolites in diabetes diagnosis and treatment |
| 04/24/2002 | EP1198589A1 Tenascin-c nucleic acid ligands |
| 04/24/2002 | EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 04/24/2002 | EP1198468A1 Stabilized viral envelope proteins and uses thereof |
| 04/24/2002 | EP1198464A1 8-PHENYL-6,9-DIHYDRO- 1,2,4]TRIAZOLO 3,4- i i /i ]PURIN-5-ONE DERIVATIVES |
| 04/24/2002 | EP1198463A2 Compounds for use in treatment of neurological disorders |
| 04/24/2002 | EP1198458A2 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 04/24/2002 | EP1198456A2 Potassium channel openers |
| 04/24/2002 | EP1198454A1 Mutilin derivatives and their use as antibacterials |
| 04/24/2002 | EP1198453A2 N-(indolcarbonyl-)piperazin derivatives |
| 04/24/2002 | EP1198451A2 Substituted phenoxyacetic acids |